Clinical trials: Motor Deficit
Niemann-Pick Disease, Type C
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
Due to different study designs, the sponsor separated Part C into this separate registration (NCT04958642), leaving Parts A/B in NCT02534844.
- Trial name
- NCT04958642
- Testing
- Adrabetadex
- Where
- 30 sites in United States, Australia and 7 more
- Volunteers
- 66 people
- Sponsor
- Mandos LLC
Aggression, Attention Deficit-Hyperactivity
Metabolic Effects of Antipsychotics in Children
The project aims to describe and compare the outcome of 12 weeks of prospective, randomized treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle, liver and adipose tissue, abdominal fat…
- Conditions
- Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders
- Trial name
- MEAC (NCT00205699)
- Testing
- risperidone, olanzapine, aripiprazole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Cerebral Palsy
Evaluating Wearable Robotic Assistance on Gait
The overarching goal of this study is to improve mobility in individuals with movement disorders through advances in wearable assistance (i.e. powered orthoses).
- Trial name
- NCT04119063
- Testing
- powered orthosis
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Northern Arizona University
Neurofibromatosis 1
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
Children with neurofibromatosis type 1 (NF1) commonly suffer from the effects of cognitive, behavioral, and motor impairments. At present, there is no specific treatment for this NF1 complication.
- Trial name
- DoDNAC (NCT04481048)
- Testing
- N-Acetyl cysteine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 4
Spinal Cord Stimulation in Spinal Muscular Atrophy
Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical…
- Trial name
- SCSinSMA (NCT05430113)
- Testing
- Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Marco Capogrosso
Leukodystrophy, White Matter Disease
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes.
- Conditions
- Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy
- Trial name
- NCT02699190
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Children's Hospital of Philadelphia
Cerebral Palsy, Sensorimotor Deficits
A Study of Neurophysiologically Based Occupational Therapy Intervention (NBOTI) for Feeding in the NCCU.
Many critically ill newborns in the neonatal intensive care (NICU) or critical care unit (NCCU) environment develop feeding and movement problems.
- Conditions
- Cerebral Palsy, Sensorimotor Deficits, Sensory Processing Disorder, Feeding Problems
- Trial name
- NBOTI (NCT00766051)
- Testing
- The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
ADHD
Lifestyle Enhancement for ADHD Program
The purpose of this study is to investigate if physical activity (PA) can increase in children with Attention Deficit/Hyperactivity Disorder (ADHD) using a modified behavioral management training (BMT) program.
- Trial name
- LEAP (NCT03690674)
- Testing
- Lifestyle Enhancement for ADHD Program
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Intermittent Explosive Disorder, Childhood Aggression
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Children with explosive aggression are often rejected by their peers, placed in special classroom, and contribute to family discord. When psychotherapy and family therapy is unsuccessful, medications are often used.
- Conditions
- Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
- Trial name
- NCT02048241
- Testing
- Parent Management Training, Intuniv
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- New York State Psychiatric Institute
Parkinson Disease
Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease
This single-center, randomized, quadruple-blinded, double-crossover comparative efficacy trial will study the effects of unilateral 50% voltage reduction in axial motor dysfunction for patients with Parkinson's disease that…
- Trial name
- NCT03462082
- Testing
- Asymmetric STN-DBS
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Toronto
Niemann-Pick Disease, Type C
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
Due to different study designs, the sponsor separated Part C into a separate registration (NCT04958642), leaving Parts A/B here in NCT02534844.
- Trial name
- NCT02534844
- Testing
- Parts A/B: Adrabetadex
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 56 people
- Sponsor
- Mandos LLC
Neurologic Disorder, Chronic Disease
Parent-Reported Symptom Assessments in Children Taking Multiple Medications
This study plans to learn about how to measure symptoms (like tiredness or rash) in children with special healthcare needs who take 5 or more medications. Sometimes symptoms change in severity over time or new symptoms develop.
- Conditions
- Neurologic Disorder, Chronic Disease, Pediatric Disorder
- Trial name
- PRSA (NCT03849066)
- Testing
- Parent-Reported Symptom Assessment
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- University of Colorado, Denver
Cerebral Palsy, Neurological Conditions
Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions
This is an open-label clinical research study of an oral glycopyrrolate liquid for the treatment of chronic moderate to severe drooling in patients with cerebral palsy or other neurological conditions.
- Conditions
- Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea
- Trial name
- NCT00491894
- Testing
- Oral Glycopyrrolate Liquid
- Where
- 7 sites in United States
- Volunteers
- 137 people
- Sponsor
- Shionogi